Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Stage IIIA Lung Carcinoma Clear all
Completed No phase listed Observational

Glucose Metabolism in Patients With Non-Small Cell Lung Cancer Treated With Targeted Therapy and Chemotherapy

NCT00450567
View directory record Official record
Conditions
Lung Cancer
Interventions
computed tomography, positron emission tomography, fludeoxyglucose F 18
Procedure · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Jul 21, 2026, 9:22 AM EDT
Active, not recruiting Phase 2 Interventional

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

NCT04701307
View directory record Official record
Conditions
Lung Small Cell Carcinoma, Neuroendocrine Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8
Interventions
Dostarlimab, Niraparib
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 21, 2026, 9:22 AM EDT
Completed Phase 1 Interventional

LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer

NCT00005858
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer
Interventions
LMB-9 immunotoxin
Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
2
States / cities
Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2019 · Synced Jul 21, 2026, 9:22 AM EDT
Completed Phase 1 Interventional Results available

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

NCT03229278
View directory record Official record
Conditions
Lymphoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Cancer, Recurrent Bladder Carcinoma, Recurrent Classical Hodgkin Lymphoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Renal Cell Carcinoma, Stage III Bladder Cancer, Stage III Lymphoma, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage III Renal Cell Cancer, Stage III Skin Melanoma, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Skin Melanoma, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Bladder Cancer, Stage IV Lymphoma, Stage IV Non-Small Cell Lung Cancer AJCC v7, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Solid Neoplasm
Interventions
Enzyme Inhibitor Therapy, Laboratory Biomarker Analysis, Nivolumab, Pembrolizumab
Drug · Other · Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Jul 21, 2026, 9:22 AM EDT
Completed No phase listed Observational

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study

NCT03707574
View directory record Official record
Conditions
Advanced Malignant Neoplasm, Advanced Melanoma, Advanced Renal Cell Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Biospecimen Collection
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
143
States / cities
Fort Lauderdale, Florida • Savannah, Georgia • Honolulu, Hawaii + 89 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jul 21, 2026, 9:22 AM EDT
Terminated Phase 1 Interventional

Oxaliplatin, Docetaxel, and Radiation Therapy in Treating Patients With Unresectable Stage II/III or Recurrent NSCLC

NCT00356941
View directory record Official record
Conditions
Lung Cancer
Interventions
docetaxel, oxaliplatin, radiation therapy
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Jul 21, 2026, 9:22 AM EDT
Completed No phase listed Observational

Psychosocial Adjustment After Radiation Therapy in Patients With Cancer

NCT00905086
View directory record Official record
Conditions
Breast Cancer, Cognitive/Functional Effects, Colorectal Cancer, Lung Cancer, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions
questionnaire administration, cognitive assessment, psychosocial assessment and care, quality-of-life assessment
Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2015 · Synced Jul 21, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

Cisplatin, Pemetrexed Disodium, and Radiation Therapy Followed by Docetaxel in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00301808
View directory record Official record
Conditions
Lung Cancer
Interventions
Cisplatin, Docetaxel, Pemetrexed disodium, Radiation therapy
Drug · Radiation
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Jul 21, 2026, 9:22 AM EDT
Completed Phase 1 Interventional

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

NCT00004074
View directory record Official record
Conditions
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix, Distal Urethral Cancer, Fallopian Tube Cancer, Gastrinoma, Glucagonoma, Inflammatory Breast Cancer, Insulinoma, Liver Metastases, Localized Unresectable Adult Primary Liver Cancer, Lung Metastases, Male Breast Cancer, Malignant Pericardial Effusion, Malignant Pleural Effusion, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Parathyroid Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Newly Diagnosed Carcinoma of Unknown Primary, Occult Non-small Cell Lung Cancer, Pancreatic Polypeptide Tumor, Primary Peritoneal Cavity Cancer, Proximal Urethral Cancer, Pulmonary Carcinoid Tumor, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adrenocortical Carcinoma, Recurrent Adult Primary Liver Cancer, Recurrent Anal Cancer, Recurrent Bladder Cancer, Recurrent Breast Cancer, Recurrent Carcinoma of Unknown Primary, Recurrent Cervical Cancer, Recurrent Colon Cancer, Recurrent Endometrial Carcinoma, Recurrent Esophageal Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Pancreatic Cancer, Recurrent Parathyroid Cancer, Recurrent Prostate Cancer, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer, Recurrent Salivary Gland Cancer, Recurrent Small Intestine Cancer, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Thyroid Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer, Skin Metastases, Small Intestine Adenocarcinoma, Somatostatinoma, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Adrenocortical Carcinoma, Stage III Bladder Cancer, Stage III Cervical Cancer, Stage III Colon Cancer, Stage III Endometrial Carcinoma, Stage III Esophageal Cancer, Stage III Follicular Thyroid Cancer, Stage III Gastric Cancer, Stage III Malignant Testicular Germ Cell Tumor, Stage III Mucoepidermoid Carcinoma of the Oral Cavity, Stage III Ovarian Epithelial Cancer, Stage III Pancreatic Cancer, Stage III Papillary Thyroid Cancer, Stage III Prostate Cancer, Stage III Rectal Cancer, Stage III Renal Cell Cancer, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Vaginal Cancer, Stage III Vulvar Cancer, Stage IIIA Anal Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Anal Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Adrenocortical Carcinoma, Stage IV Anal Cancer, Stage IV Bladder Cancer, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Endometrial Carcinoma, Stage IV Esophageal Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Gastric Cancer, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Pancreatic Cancer, Stage IV Papillary Thyroid Cancer, Stage IV Prostate Cancer, Stage IV Rectal Cancer, Stage IV Renal Cell Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Stage IVB Vulvar Cancer, Thyroid Gland Medullary Carcinoma, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer, Urethral Cancer Associated With Invasive Bladder Cancer, WDHA Syndrome
Interventions
recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Jul 21, 2026, 9:22 AM EDT
Completed No phase listed Observational

Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer

NCT00897793
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
Interventions
venipuncture, radiation therapy
Procedure · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Jul 21, 2026, 9:22 AM EDT
Completed Phase 3 Interventional

S9900: Surgery With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer

NCT00004011
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, conventional surgery
Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
267
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 197 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Jul 21, 2026, 9:22 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT04819100
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Selpercatinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
15
States / cities
Los Angeles, California • Stockton, California • Torrance, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Jul 21, 2026, 9:22 AM EDT
Not listed Phase 2 Interventional Results available

Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT03048500
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage III Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Laboratory Biomarker Analysis, Metformin Hydrochloride, Nivolumab
Other · Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Chicago, Illinois • Lake Forest, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Jul 21, 2026, 9:22 AM EDT
Active, not recruiting Phase 3 Interventional

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

NCT02201992
View directory record Official record
Conditions
ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Interventions
Clinical Observation, Crizotinib, Laboratory Biomarker Analysis
Other · Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2036
U.S. locations
1613
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 978 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Jul 21, 2026, 9:22 AM EDT
Recruiting Phase 2 Interventional

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

NCT04892953
View directory record Official record
Conditions
Stage III Lung Cancer AJCC v8, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IIIC Lung Cancer AJCC v8
Interventions
Carboplatin, Durvalumab, Gemcitabine, Local Consolidation Therapy, Nab-paclitaxel, Paclitaxel, Pemetrexed, Quality-of-Life Assessment, Questionnaire Administration
Drug · Biological · Procedure + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Jul 21, 2026, 9:22 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Using Urine Samples to Identify Lung Cancer

NCT06033248
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
urine sample
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 90 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 21, 2026, 9:22 AM EDT
Completed Not applicable Interventional

Supportive Care Intervention (ROAR-LCT) for Patients With Stage IIIA, IIIB, and IV Lung Cancer, ROAR-LCT Trial

NCT05339022
View directory record Official record
Conditions
Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Small Cell Carcinoma, Extensive Stage Lung Small Cell Carcinoma, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Lung Small Cell Carcinoma
Interventions
Best Practice, Exercise Intervention, Physical Therapy, Quality-of-Life Assessment, Questionnaire Administration, Relaxation Therapy
Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Jul 21, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer

NCT02904954
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Durvalumab, Durvalumab plus SBRT
Drug · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Jul 21, 2026, 9:22 AM EDT
Terminated Phase 1 Interventional

Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer

NCT00042835
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
cisplatin, etoposide, erlotinib hydrochloride, radiation therapy, docetaxel, paclitaxel, carboplatin, laboratory biomarker analysis
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Jul 21, 2026, 9:22 AM EDT
Terminated Phase 2 Interventional Results available

Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer

NCT04396535
View directory record Official record
Conditions
Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Bintrafusp Alfa, Docetaxel
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Jul 21, 2026, 9:22 AM EDT
Completed Phase 1 Interventional

Chemotherapy and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer

NCT00022308
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, irinotecan hydrochloride, radiation therapy
Drug · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
8
States / cities
Millville, New Jersey • Mount Holly, New Jersey • Red Bank, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2013 · Synced Jul 21, 2026, 9:22 AM EDT
Completed Not applicable Interventional

Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer

NCT00372840
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Malignant Mesothelioma, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment, Thymoma and Thymic Carcinoma
Interventions
educational intervention, psychosocial assessment and care, quality-of-life assessment
Other · Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Jul 21, 2026, 9:22 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT00334815
View directory record Official record
Conditions
Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Large Cell Carcinoma, Lung Squamous Cell Carcinoma, Minimally Invasive Lung Adenocarcinoma, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Interventions
Bevacizumab, Cisplatin, Docetaxel, Etoposide, Filgrastim, Pegfilgrastim, Radiation Therapy
Biological · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2027
U.S. locations
61
States / cities
Mobile, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 21, 2026, 9:22 AM EDT
Active, not recruiting Phase 2 Interventional

Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy

NCT04716946
View directory record Official record
Conditions
NSCLC, Non-small Cell Lung Cancer, Lung Cancer, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IIIA, PD-L1 Gene Mutation
Interventions
Durvalumab, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
8
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jul 21, 2026, 9:22 AM EDT